PDLI
NASDAQPDL BioPharma, Inc.
PDL BioPharma, Inc. (PDLI) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for PDLI in the last 30 days. The most recent was published Apr 16, 2025.
Latest news
25 items- PREngine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual MeetingIntends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port
- PRBiomX Announces the Appointment of Susan Blum to its Board of DirectorsCAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance
- PRApexigen Announces Appointment of Francis Sarena as Chief Operating OfficerSAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut
- SECSEC Form SC TO-I/A filedSC TO-I/A - PDL BIOPHARMA, INC. (0000882104) (Subject)
- 13D/GSEC Form SC 13G/A filedSC 13G/A - PDL BIOPHARMA, INC. (0000882104) (Subject)
- 13D/GSEC Form SC 13G/A filedSC 13G/A - PDL BIOPHARMA, INC. (0000882104) (Subject)
- SECSEC Form EFFECT filedEFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form EFFECT filedEFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form EFFECT filedEFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form EFFECT filedEFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form EFFECT filedEFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form EFFECT filedEFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form EFFECT filedEFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
- INSIDERSEC Form 4: L.P. Capital Point Silver bought $383,475 worth of Common Stock (187,061 units at $2.05)4 - PDL BIOPHARMA, INC. (0000882104) (Issuer)
- SECSEC Form POS AM filedPOS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form POS AM filedPOS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form POS AM filedPOS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form POS AM filedPOS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form POS AM filedPOS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form POS AM filedPOS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form POS AM filedPOS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form EFFECT filedEFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form EFFECT filedEFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form POS AM filedPOS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
- SECSEC Form POS AM filedPOS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
PDLI FAQ
6 questionsWhat is the latest news on PDLI?
Quantisnow has not tracked any new filings, ratings or press releases for PDLI in the last 30 days. The most recent wire item was published on April 16, 2025.Where does PDLI stock trade?
PDL BioPharma, Inc. (PDLI) is listed on NASDAQ.What sector and industry is PDLI in?
PDL BioPharma, Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did PDL BioPharma, Inc. go public?
PDL BioPharma, Inc. (PDLI) completed its IPO in 1992.What companies are similar to PDLI?
Notable peers in the same industry include EXEL (Exelixis Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), AMGN (Amgen Inc.), RVMD (Revolution Medicines Inc.). Compare PDLI side-by-side with any of them on Quantisnow.How can I track PDLI on Quantisnow?
Quantisnow aggregates PDL BioPharma, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PDLI to receive live email and push alerts on every new disclosure.